AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22316314
Drug: Low-dose vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vitamin D supplementation (average daily dose 200 IU)
Trial: 22316314
Drug: Low-dose vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vitamin D supplementation
Trial: 15101856
Drug: Ropivacaine-HCl 5
RxNorm normalized name: Ropivacaine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine-HCl 5 mg ml(-1)
Trial: 15101856
Drug: Levobupivacaine-HCl 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine-HCl 5 mg ml(-1)
Trial: 15101856
Drug: Bupivacaine-HCl 5
RxNorm normalized name: Bupivacaine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine-HCl 5 mg ml(-1)
Trial: 12221843
Drug: Medication plus
RxNorm normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication plus carbon dioxide baths
Trial: 9818665
Drug: Intraarticular hyaluronic
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarticular hyaluronic acid (HA; Hyalgan) 20 mg each for 5 weekly injections
Trial: 8131527
Drug: Terbutaline dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline dry powder inhaled via Turbuhaler (2.5 mg)
Trial: 8131527
Drug: Terbutaline inhaled
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline inhaled via CFC inhaler and Nebuhaler (2.5 mg)
Trial: 2401100
Drug: Naloxone, 4
RxNorm normalized name: Buprenorphine-Naloxone, 4 mg-1 mg sublingual film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone, 4 mg bolus and 6 mg/h intravenously
Trial: 2401100
Drug: Saline, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline, administered intravenously
Trial: 2401100
Drug: Naloxone, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone, administered intravenously
Trial: 7437134
Drug: FK 33‐824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK 33‐824 (1.25 mg, i.m.)
Trial: 7437134
Drug: Morphine HCL
RxNorm normalized name: morphine HCl
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine HCL (20 mg, i.m.)
Trial: 27910088
Drug: Bupivacaine (GON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (GON blockade administered four times, once per week)
Trial: 27910088
Drug: Placebo (saline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline, GON blockade administered four times, once per week)
Trial: 25688820
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (1 gram)
Trial: 15167329
Drug: Home glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home glucose records in computer‐assisted insulin dose adjustment
Trial: 15167329
Drug: Pocket‐sized insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pocket‐sized insulin dosage computers
Trial: 9484382
Drug: Intramuscular ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketorolac 60 mg
Trial: 8707552
Drug: Meperidine 50
RxNorm normalized name: meperidine 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 50 mg plus promethazine 25 mg
Trial: 23590647
Drug: Psychoprophylaxis childbirth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoprophylaxis childbirth preparation (coaching training)
Trial: 23590647
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care antenatal preparation (no coaching training)
Trial: 21406094
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol 100 mcg twice daily started at induction of anaesthesia and continued for 72 hours thereafter
Trial: 21406094
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol 100 mcg twice daily
Trial: 16890832
Drug: Scheduled treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled treatment interruptions
Trial: 24962326
Drug: In-Prison buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-Prison buprenorphine Treatment Condition
Trial: 24342495
Drug: Antithrombin at
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin at a dose of 30 IU/kg per day for three days
Trial: 24342495
Drug: Antithrombin treatment
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin treatment
Trial: 17394534
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and Glibenclamide
Trial: 17300951
Drug: Atorvastatin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin plus aspirin combined therapy
Trial: 8783345
Drug: Teicoplanin 10
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin 10 mg/kg/day (Group A)
Trial: 8783345
Drug: Teicoplanin 20
RxNorm normalized name: Teicoplanin 200 mg powder for solution for injection vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin 20 mg/kg/day (Group B)
Trial: 3006226
Drug: Intravenous Acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Acyclovir (ACV) 10 mg/kg every 8 h for 7 days
Trial: 26865043
Drug: Ticagrelor 180
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 180 mg loading dose, followed by 90 mg twice daily after PCI
Trial: 26865043
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg loading dose, followed by 75 mg once daily after PCI
Trial: 22410586
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block with 0.5% ropivacaine 1.5 mg/kg
Trial: 14713566
Drug: Biological interventions
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological interventions
Trial: 6339349
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml HBIG at birth, 3 months, and 6 months
Trial: 6339349
Drug: 1.0 ml
RxNorm normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 ml HBIG at birth only
Trial: 31504693
Drug: Daytime protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daytime protein (30 g casein) 30 min post-resistance exercise
Trial: 31504693
Drug: Presleep placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presleep placebo (0 g casein) 30 min before bed
Trial: 28587789
Drug: Once-weekly albiglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly albiglutide
Trial: 14981370
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptives with desogestrel (DG/EE)
Trial: 14981370
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptives with levonorgestrel (LNG/EE)
Trial: 14981370
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptives with both preparations (LNG/EE and DG/EE)
Trial: 11712093
Drug: Re-treatment with
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-treatment with artemisinin
Trial: 11712093
Drug: Artemisinin treatment
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin treatment
Trial: 9151026
Drug: Heparin treated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin treated circuits (Duraflo II)
Trial: 7951083
Drug: Berodual (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berodual (1 dose = 0.02 mg ipratropium bromide + 0.05 mg fenoterol), administered 3 x 1 dose/daily for 14 days
Trial: 7951083
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (Atrovent, 1 dose = 0.02 mg), administered 3 x 2 doses/daily for 14 days
Trial: 7951083
Drug: Fenoterol (Berotec,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (Berotec, 1 dose = 0.2 mg), administered 3 x 2 doses/daily for 14 days
Trial: 29303771
Drug: Medium-term biological
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-term biological variation assessment (blood sampling once/week for five consecutive weeks)
Trial: 29303771
Drug: Short-term biological
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term biological variation assessment (blood sampling once/day for five consecutive days)
Trial: 17217716
Drug: Dobutamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine infusion (10 microg kg‐1 min‐1, increasing to 40 microg kg‐1 min‐1 at 3 min intervals)
Trial: 14594938
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy (HF group), fraction size 1.2 Gy, mean total dose 73.4 Gy (range, 66-79.2 Gy)
Trial: 14594938
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy (HF group)
Trial: 14594938
Drug: Conventional fractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fractionated radiation therapy (CF group), fraction size 1.8-2.0 Gy, mean total dose 65.4 Gy (range, 60-70 Gy)
Trial: 14594938
Drug: Conventional fractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fractionated radiation therapy (CF group)
Trial: 7901585
Drug: Albendazole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (10 mg/kg daily) for 1 month (group A)
Trial: 7901585
Drug: Albendazole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (10 mg/kg daily) for about 3 months (group B)
Trial: 2939116
Drug: etodolac 50‐600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etodolac 50‐600 mg/d
Trial: 25085036
Drug: Ketamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (1 mg/kg bolus)
Trial: 17993823
Drug: Daily-wear basis
RxNorm normalized name: ZINC OXIDE 22.7 g in 100 g TOPICAL LOTION [ETHICAL ZINC DAILY WEAR LIGHT SUNSCREEN SPF-50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily-wear basis
Trial: 16385384
Drug: s.c. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. infusion of saline (SAL)
Trial: 16385384
Drug: s.c. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. infusion of GLP‐1 (2.4 pmol kg(‐1) min(‐1); LSC)
Trial: 16385384
Drug: s.c. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. infusion of GLP‐1 (2.4 pmol kg(‐1) min(‐1)) in combination with a DPP‐4 inhibitor (IB)
Trial: 16385384
Drug: i.v. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of GLP‐1 (1.2 pmol kg(‐1) min(‐1); IV)
Trial: 16385384
Drug: s.c. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. infusion of GLP‐1 (9.6 pmol kg(‐1) min(‐1); HSC)
Trial: 1633753
Drug: Triazolam (0.32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.32 mg/70 kg)
Trial: 1633753
Drug: Triazolam (0.1‐0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.1‐0.75 mg/70 kg)
Trial: 6241386
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (group II)
Trial: 6241386
Drug: Total coronary
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total coronary occlusion treatment
Trial: 30202408
Drug: Gross myofascial
RxNorm normalized name: Ostericum grosseserratum root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gross myofascial release (MFR) of neck and upper limb in addition to conventional therapy (hot moist pack, TENS, stretching and strengthening exercises) for 6 consecutive days.
Trial: 30202408
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (hot moist pack, TENS, stretching and strengthening exercises) for 6 consecutive days.
Trial: 21320855
Drug: High volume
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High volume feeds at 300 ml/kg/day
Trial: 21320855
Drug: Standard volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard volume feeds at 200 ml/kg/day
Trial: 20561621
Drug: Standard-volume PEG-electrolyte
RxNorm normalized name: ELECTROLYTES/PEG-3350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-volume PEG-electrolyte solution
Trial: 20561621
Drug: Split-dosage regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dosage regimen
Trial: 20561621
Drug: Fair/poor preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fair/poor preparation
Trial: 20561621
Drug: Non-split-dosage arm
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-split-dosage arm
Trial: 20561621
Drug: Non-split-dosage bowel
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-split-dosage bowel preparation schedule
Trial: 17439381
Drug: TLC diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC diet plus soy nuts (25 g soy protein and 101 mg aglycone isoflavones)
Trial: 8820174
Drug: Apomorphine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine (0.5 mg sc)
Trial: 30260273
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg) administered via intravenous infusion
Trial: 26840331
Drug: Placebo (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (200 mg/day)
Trial: 23619342
Drug: Se‐75‐homocholic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Se‐75‐homocholic acid taurine (Se‐75‐HCAT) administered orally
Trial: 20350153
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) as a full-mouth procedure after scaling and root planing (SRP)
Trial: 20350153
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated with photosensitizer solution without laser irradiation
Trial: 19052402
Drug: Azathioprine 100
RxNorm normalized name: azathioprine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine 100 mg daily (group A)
Trial: 19052402
Drug: Betamethasone 2
RxNorm normalized name: betamethasone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone 2 mg daily (group B)
Trial: 15876902
Drug: Citalopram 40
RxNorm normalized name: citalopram 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 40 mg/d
Trial: 10380021
Drug: Intravenous 500
RxNorm normalized name: Cytovene-IV 500 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 500 mg acetazolamide (Diamox) (Group 1)
Trial: 1998656
Drug: niacin/colestipol therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: niacin/colestipol therapy
Trial: 30089614
Drug: Highest oxLDL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest oxLDL quartile (≥28.81 μg/dL)
Trial: 24999157
Drug: Combined albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined albendazole (15 mg/kg per day) plus praziquantel (50 mg/kg per day)
Trial: 24999157
Drug: Standard albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard albendazole (15 mg/kg per day)
Trial: 24999157
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose albendazole (22.5 mg/kg per day)
Trial: 22553354
Drug: Betulinic acid
RxNorm normalized name: Betulinic Acid
DrugBank: Betulinic Acid (DB12480)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betulinic acid (1 to 10 μmol/L)
Trial: 16088266
Drug: Multidisciplinary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary treatment and repeated thermal therapy (far-infrared ray dry sauna therapy and post-sauna warming, once a day for 4 weeks)
Trial: 16088266
Drug: Multidisciplinary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary treatment (cognitive behavioral therapy, rehabilitation, and exercise therapy)
Trial: 12805913
Drug: Lidocaine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (600 mg + 5 mg/ml adrenaline)
Trial: 12805913
Drug: Mepivacaine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine (600 mg + 5 microg/ml adrenaline)
Trial: 9505892
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose enteric coated pancreatin enzyme supplementation
Trial: 2128929
Drug: Conventional preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional preparation (CP)
Trial: 2128929
Drug: Conventional preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional preparation (CP) with Sennosides
Trial: 2128929
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy utilizing Metronidazole
Trial: 2128929
Drug: 24-hour antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour antibiotic therapy utilizing Metronidazole (1.5 g) and/or Cefotaxime (4 g)
Trial: 75643
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of any two diagnostic methods
Trial: 19884554
Drug: Model for
RxNorm normalized name: Model AA 2012 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model for response prediction including RRM1, ERCC1, and treatment arm
Trial: 17084905
Drug: Family-focused psychoeducation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused psychoeducation and pharmacotherapy
Trial: 8240465
Drug: ibuprofen/placebo (stomach)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen/placebo (stomach) 0.9 ± 0.1
Trial: 8240465
Drug: ibuprofen/placebo (duodenum)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen/placebo (duodenum) 0.0 ± 0.0
Trial: 8240465
Drug: ibuprofen/ranitidine (stomach)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen/ranitidine (stomach) 0.8 ± 0.1
Trial: 8240465
Drug: ibuprofen/ranitidine (duodenum)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen/ranitidine (duodenum) 0.1 ± 0.1
Trial: 8240465
Drug: ibuprofen/placebo (duodenum)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen/placebo (duodenum) 0.2 ± 0.1
Trial: 8240465
Drug: ibuprofen/ranitidine (stomach)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen/ranitidine (stomach) 0.9 ± 0.1
Trial: 31548130
Drug: Initial mpMRI
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial mpMRI followed by biopsy for negative mpMRI (PI-RADS 1-2) if the 4Kscore was >18% or PSAd was >0.10ng/ml/cm3
Trial: 31548130
Drug: PSAd <0.10ng/ml/cm3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSAd <0.10ng/ml/cm3
Trial: 17007757
Drug: Oral steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroid group (prednisolone 2mg/kg/day on alternate days, tapered over 8 weeks)
Trial: 17007757
Drug: Intra-lesional steroid
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-lesional steroid group (triamcinolone 1 to 5 mg/kg, max 30mg, six injections monthly)
Trial: 17007757
Drug: Oral steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroid group
Trial: 17007757
Drug: Intra-lesional steroid
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-lesional steroid group
Trial: 9399753
Drug: 6-mercaptopurine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-mercaptopurine (50 mg daily)
Trial: 15362027
Drug: mesalamine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mesalamine (3 g daily)
Trial: 11493295
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel dressings
Trial: 11493295
Drug: Nonsilicone gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsilicone gel dressings
Trial: 2884811
Drug: Diazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (10 mg/day)
Trial: 31771385
Drug: B+P (biological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B+P (biological management with prevention)